We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00574015
Recruitment Status : Completed
First Posted : December 14, 2007
Last Update Posted : March 24, 2014
Information provided by (Responsible Party):

December 13, 2007
December 14, 2007
March 24, 2014
December 2007
January 2013   (Final data collection date for primary outcome measure)
VAS determination of pain at 30 minutes following intervention [ Time Frame: 30 minutes ]
Same as current
Complete list of historical versions of study NCT00574015 on ClinicalTrials.gov Archive Site
Numeric scale report or pain Number of prescribed analgesic pills taken [ Time Frame: 24-36 hours following intervention ]
Same as current
Not Provided
Not Provided
The Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache
The Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache

This study will compare the degree of pain control provided by two techniques for persons with toothache in an emergency department. The two techniques include;

  • standard oral narcotic pain medication
  • numbing the tooth with local anesthetic by needle injection

Background: Toothache is a common complaint among patients presenting to the emergency department. There are two commonly employed methods of alleviating this severe form of pain. Oral opioid analgesia is the most commonly utilized strategy for treating this pain. However, many emergency physicians and dentists employ a local anesthetic technique known as supraperiosteal nerve block. This study will compare the relative efficacy of these techniques.

Patients meeting enrollment criteria will be randomized to either receive a supraperiosteal nerve block or oral hydrocodone 10 mg/acetaminophen 650 mg. They will otherwise be managed identically. Reduction of pain scores between entry and 30 minutes post intervention will be compared as well as numeric pain scores obtained by phone contact 24 hours later. Secondary outcomes will include the proportion of individuals from each group filling prescriptions for pain medication and the number of pain pills taken.

Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Drug: hydrocodone/acetaminophen
    oral hydrocodone 10 mg/acetaminophen 650 mg
    Other Names:
    • Lortab
    • Vicodin
  • Drug: bupivacaine (supraperiosteal nerve block)
    Administration of Bupivacaine 0.5% 2 ml adjacent to tooth root
    Other Name: Marcaine
  • Active Comparator: oral
    administration of oral analgesia
    Intervention: Drug: hydrocodone/acetaminophen
  • Experimental: Dental Block
    Administration of supraperiosteal nerve block to effected tooth
    Intervention: Drug: bupivacaine (supraperiosteal nerve block)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
January 2013
January 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Involvement of a single tooth
  • Percussive tenderness of the crown of the suspect tooth

Exclusion Criteria:

  • Age younger than 18 years
  • Women who are breast feeding
  • Allergy or intolerance to hydrocodone, bupivacaine or acetaminophen
  • Pregnancy
  • Involvement of multiple teeth
  • Pain resulting from pericoronitis.
  • Pain resulting from dental trauma occurring less than 90 days prior
  • Pain of more than 96 hours duration
  • Facial or neck swelling or tenderness
  • Alteration in phonation
  • Cognitive impairment
  • Concurrent use of opiate analgesics
  • Impairment of liver function
  • Consumption of more than 4 grams of acetaminophen in the past 24 hours.
  • Patients who are visually impaired.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Wayne Triner, Albany Medical College
Albany Medical College
Not Provided
Principal Investigator: Wayne R Triner, DO, MPH Albany Medical College
Albany Medical College
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP